Paul Tudor Jones Sarepta Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $200 Billion
- Q3 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 68,832,803 shares of SRPT stock, worth $1.29 Billion. This represents 0.66% of its overall portfolio holdings.
Number of Shares
68,832,803
Previous 50,851
135261.75%
Holding current value
$1.29 Billion
Previous $869,000
152536.13%
% of portfolio
0.66%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SRPT
# of Institutions
421Shares Held
85.8MCall Options Held
5.66MPut Options Held
6.11M-
Vanguard Group Inc Valley Forge, PA10.8MShares$203 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$194 Million0.04% of portfolio
-
State Street Corp Boston, MA5.3MShares$99.8 Million0.0% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.69MShares$50.5 Million0.49% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.65MShares$49.8 Million0.07% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.65B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...